Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial

BACKGROUND: Immunotherapy (Programmed cell death 1 blockade) has entered the ranks of advanced esophageal cancer first-line treatment; however, little is known about the efficacy of PD-1 inhibitor as neoadjuvant therapy in resectable esophageal squamous cell carcinoma (ESCC). We aim to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhi, Ye, Jinjun, Li, Hui, Gu, Dayong, Du, Mingyu, Ai, Dashan, Chen, Wei, Fang, Ying, Xu, Xinyu, Bai, Chenguang, Zhao, Kuaile, Zhou, Guoren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606329/
https://www.ncbi.nlm.nih.gov/pubmed/36311804
http://dx.doi.org/10.3389/fimmu.2022.1031171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606329/
https://www.ncbi.nlm.nih.gov/pubmed/36311804
http://dx.doi.org/10.3389/fimmu.2022.1031171

Ejemplares similares